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Novel Handheld Magnetometer 
Probe Based on Magnetic 
Tunnelling Junction Sensors for 
Intraoperative Sentinel Lymph 
Node Identification
A Cousins1, G. L. Balalis2, S. K. Thompson3, D. Forero Morales3, A. Mohtar4, A. B. Wedding3 
& B. Thierry1
Using magnetic tunnelling junction sensors, a novel magnetometer probe for the identification of the 
sentinel lymph node using magnetic tracers was developed. Probe performance was characterised 
in vitro and validated in a preclinical swine model. Compared to conventional gamma probes, the 
magnetometer probe showed excellent spatial resolution of 4.0 mm, and the potential to detect 
as few as 5 μ g of magnetic tracer. Due to the high sensitivity of the magnetometer, all first-tier 
nodes were identified in the preclinical experiments, and there were no instances of false positive 
or false negative detection. Furthermore, these preliminary data encourage the application of the 
magnetometer probe for use in more complex lymphatic environments, such as in gastrointestinal 
cancers, where the sentinel node is often in close proximity to other non-sentinel nodes, and high 
spatial resolution detection is required.
In the Tumour Node Metastasis (TNM) classification system, the lymphatic system plays a central role 
in the standard of care for breast cancer and melanoma. Of most prognostic significance is the sentinel 
lymph node (SLN): the first-tier lymph node to receive drainage from a primary tumour. The presence 
of metastasis in the SLN has a strong prognostic value in a number of solid cancers1–3. If the SLN can be 
accurately identified and distinguished from surrounding or lower-tier nodes, then a much more targeted 
approach to cancer staging and treatment is achievable. In order to identify the SLN, lymphotropic con-
trast agents must be used, as the ‘sentinel’ status cannot be determined based on anatomical features or 
location alone. Currently the gold standard lymphotropic contrast agents for breast cancer and melanoma 
are low soluble blue dyes and radioactive colloids (usually 99mTc-based). The role of the dyes is to vis-
ually guide the surgery by staining the lymphatic vessels leading from the tumour site and subsequently, 
stain the SLN. Radioactive tracers have the advantage that gamma camera or SPECT imaging can be 
performed preoperatively to provide the surgical team with a lymphatic ‘roadmap’. During the surgery, 
the location of the SLN can then be confirmed with a handheld gamma-detecting probe. Both contrast 
agents may be used independently, but greater accuracy can be achieved if they are used simultaneously4. 
Whilst these gold standard contrast agents have well-established efficacy in breast cancer and melanoma 
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SLN identification, they have limited application in cancer types with more complex lymphatic draining 
routes, due to radiation shine-through affecting spatial resolution and accuracy.
In order to overcome the challenges associated with applying the SLN concept beyond breast cancer 
and melanoma, alternative approaches are currently being investigated4. Due to the high quality mag-
netic signal and validated use in clinical trials5–7, iron oxide nanoparticle-based magnetic tracers show 
great promise as a real-world alternative to conventional lymphotropic contrast agents. One particular 
advantage to using magnetic tracers is that the SLN detection protocol remains analogous to the proto-
col currently performed using radioactive tracers (preoperative roadmap imaging and detection with a 
handheld probe). Furthermore, magnetic tracers eliminate the need for ionising radiation sources and 
therefore reduce the logistical issues currently associated with the manufacturing, handling, and licens-
ing required to administer radioactive tracers. In the magnetic tracer alternative, magnetic resonance 
imaging (MRI) can be readily used instead of gamma cameras for preoperative localisation of the SLN, 
providing high-resolution imaging and consequently better anatomically detailed images compared to 
gamma cameras.
To enable intraoperative detection of the SLN, handheld magnetometer probes are required in place 
of gamma probes. A number of magnetometer probe technologies have been proposed using a range of 
sensing technologies – from Hall effect sensors8–10 and SQUID sensors11, to the current embodiment of 
a commercially available instrument, the SentiMag probe, which uses precisely constructed induction 
coil sensors12. The SentiMag probe provides a notable example of the application of magnetic tracers 
and magnetometer detection of sentinel nodes and has been demonstrated in a large clinical breast 
cancer trial6 and recently, in a clinical prostate cancer trial7. A common compromise that exists with 
conventional magnetometer technology (Hall effect, giant magnetoresistor, fluxgate, induction coil, or 
SQUID based sensors) is that cost and sensitivity are often inversely related. For example, whilst some 
commercial Hall effect sensors can be bought for less than $1, their sensitivity is often limited to the 
millitesla range. Alternatively, the cost for SQUID magnetometers can extend into hundreds of thousands 
of dollars, which is a reflection of their superior (femtotesla) sensitivity.
Magnetic tunnelling junction (MTJ) sensing technology is as an ideal compromise between cost and 
sensitivity. Limited by the nanofabrication techniques required to produce them, MTJ sensors were not 
developed until the early 1990s, with commercial products available in limited supply from the early 
2000s. MTJ sensors utilise the spin tunnel magnetoresistance phenomenon, with passive electrical char-
acteristics dependent on the net magnetic flux parallel to the sensor’s sensing axis. Like Hall effect and 
giant magnetoresistor sensors, they can be integrated into surface-mounted packages for electronics, 
or as bare die can be used to make magnetometers with a sensing area only tens of microns wide13 In 
the last 15 years, development of MTJ technology has been rapid, with room temperature tunnelling 
magnetoresistance (an indicator of MTJ sensitivity) increasing from approximately 40%14 to over 600%15 
Currently available commercial MTJ sensors, such as the STJ-240 (MicroMagnetics, Massachusetts, USA) 
can be bought off-the-shelf with room temperature magnetoresistance as high as 200% and capable of 
measuring nanotesla (nT) fields, yet (at the time of writing) only cost US$50. With such developments, 
magnetometers developed using MTJ technology have the potential to create an economically competi-
tive alternative to conventional induction coil and, in particular, fluxgate magnetometers.
Importantly, MTJ technology also has the potential to offer higher spatial resolution in the detection 
of small accumulations of magnetic tracers. In order to distinguish individual lymph nodes in tightly 
packed clusters, the overall spatial resolution of handheld probes must be less than the average distance 
between nodes (often taken as < 25 mm for gamma probes used in breast cancer and melanoma proce-
dures16). Overall spatial resolution (i.e. for gamma probes) is measured as the full width half maximum 
(FWHM) of a device’s response curve when scanned laterally over a point source. Due to the radiant 
nature of gamma tracer signals and the size of detectors used in gamma probes, spatial resolution of 
commercial probes may vary from 13 – 20 mm depending on the manufacturer17 While satisfactory for 
detecting the SLN in breast cancer and melanoma, spatial resolutions of this order become problem-
atic in complex lymphatic environments such as oesophageal cancer, where approximately 90% of the 
SLNs are within 30 mm of the primary tumour18 and are often clustered in close proximity to other 
non-sentinel nodes.
Taking these limitations into account, a novel magnetometer probe designed using advanced MTJ 
sensors has been developed to enable the accurate and reliable detection of small quantities of magnetic 
tracers in the SLN. More specifically, the characteristic features of MTJ sensors are used here to create a 
sensitive, high spatial resolution, and cost-effective alternative to other magnetometer designs aimed at 
replacing gamma probe technology.
Results
Constructing the magnetometer probe. A custom double-sided printed circuit board (PCB) was 
designed to make the probe’s sensor, and to fit securely inside the hollow core of a bobbin-shaped electro-
magnet. For the construction of the magnetometer probe sensor, 4 single-axis MTJ sensors (two sensors 
per side of the circuit board) were arranged into a full-bridge Wheatstone configuration on one end of 
the PCB. The sensor bridge had a total resistance of 1.5 kΩ (in zero field) with an input current of 3.3 mA. 
The sensor PCB was mounted inside a 90-turn cylindrical electromagnet with ferrous core, which formed 
the tip of the probe (Fig.  1a). From finite element analysis of the electromagnet’s hollow-core bobbin 
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design, the magnetic flux density peaks in magnitude approximately 2.5 mm from the tip of the probe, 
before decaying in a manner more comparable to solid-core electromagnets (Fig. 1b).
The electromagnet at the tip of the magnetometer probe was used to excite the magnetic tracer with 
an alternating parallel/antiparallel magnetic field (square wave alternating current, 180 Hz, 50% duty 
cycle). This approach was chosen such that the magnetisation signal from the magnetic tracer (in phase 
with the electromagnet) could be distinguished from background signals such as the baseline magnetic 
signal from the electromagnet, 50 Hz mains power noise, and Earth’s background magnetic field, which 
are often orders of magnitude greater than the magnetic tracer signal. By processing the Wheatstone 
bridge signal using high gain, high Q active filters, any signals not in phase with the switching electro-
magnet (i.e. the noise) could be strongly attenuated. Finally, the filtered signal was converted to a DC 
signal proportionate to the magnitude of the signal from the magnetic tracers; hence changes in the 
magnetometer probe output could indicate both the presence and quantity of magnetic tracer in the 
vicinity of the probe tip.
Measuring the magnetometer probe detection limit. In order to measure the detection limit, a 
series of magnetic phantoms were made by drying various quantities of a magnetic tracer stock.
The detection threshold was defined as the quantity of magnetic tracer detected by the probe with 
a signal to noise ratio (SNR) of 2.0. Detection threshold measurements for the sensor bridge were per-
formed using three phantoms of varying magnetic tracer quantity (0.3 mg, 0.7 mg, and 1.3 mg). A custom 
rotating stage was used to measure multiple phantoms in sequence and control the distance between the 
probe and phantoms between measurements. The probe was mounted vertically above the sample stage, 
and positioned such that the sensor bridge was 4.0 mm from the dried particles of each passing phantom. 
This distance value was chosen as a practical probe-to-node distance due to the likely presence of adipose 
tissue or adventitia surrounding SLNs. Based on the magnitude and noise level of signal for the three 
measured phantoms, a 50 μ g detection threshold at 4.0 mm distance was calculated (Fig. 2).
Longitudinal range measurement. Longitudinal sensitivity of a device is the ability to resolve the 
presence of a signal at distance, and hence is a measurement of the signal from a source as it is moved 
further away from the tip of the probe. The MTJ magnetometer probe longitudinal sensitivity was meas-
ured using a concentrated 10 mg phantom (to improve signal to noise ratio), which consisted of 0.1 mL of 
colloidal tracer in a 1.5 mL microcentrifuge tube. A liquid phantom was selected as it better represented 
Figure 1. MTJ magnetometer probe schematic diagram. (a) The MTJ sensor bridge is mounted on the 
end of a small double-sided PCB, and positioned inside a cylindrical electromagnet’s aperture, forming the 
probe tip. The electromagnet consisted of a 90-turn coil wound onto a ferrous core and was used to excite 
magnetic nanoparticles in either parallel or antiparallel magnetisation with respect to the sensing axis of 
the probe. (b) Due to the hollow core of the bobbin-shaped electromagnet, from finite element analysis, 
the magnetic signal can be seen to peak at approximately 2.5 mm from the probe tip, before decaying in a 
manner similar to that of solid-core electromagnets.
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the volume of a small lymph node, compared to the thin film of tracer in dried phantoms used in detec-
tion limit measurements. The probe was mounted horizontally, and displacement (0.0 mm to 7.5 mm 
from the probe tip) was controlled via a 2-inch translational stage driven by a DC motor. The phantom 
was then mounted horizontally on one end of a 30 cm rigid plastic strip with the other end attached to 
the stage, to act as a spacer and attenuate any magnetic interference from the stage / motor that may be 
measured by the probe. From the measured data (Fig. 3), it can be seen that the magnetic signal from 
the phantom has a short range, with the signal decaying to 50% at a distance of just 1.0 mm, and below 
a SNR of 2.0 at approximately 5.1 mm.
Lateral response curve measurement. For conventional gamma probes, the spatial resolution is 
a measure of the lateral response of the probe, i.e. the FWHM of the signal obtained by scanning a 
small point source phantom past the probe at a fixed distance. Likewise, the spatial resolution of the 
magnetometer probe was quantified by measuring the response curve resulting from scanning a small 
1.0 mg dried-tracer phantom. The translational stage was again used to provide controlled displacement 
of the phantom. The probe was mounted vertically during measurements such that phantom displace-
ment was perpendicular to the sensing axis of the sensor bridge. Due to the high attenuation of mag-
netic signals with distance, the phantom-probe distance was reduced to 1.0 mm (longitudinal distance), 
and scanned ± 6.0 mm (lateral distance) from the centre of the probe (x = 0). From the resultant lateral 
response curve (Fig. 4), a spatial resolution of 4.0 mm for the magnetometer probe was measured.
Ex vivo measurement of swine lymph nodes. Evaluation of the magnetometer probe in vivo was 
determined using large animal (swine) preclinical studies. To begin with, a 10 mg quantity (20 mg/mL) 
of magnetic tracer was injected intradermally at a pre-marked site on the dorsal surface above each 
hind hoof of a single swine. T1 and T2* MRI sequences of the hind leg and groin region were acquired 
Figure 2. Probe limit of detection. By measuring a range of magnetic tracer quantities at a fixed distance 
of 4.0 mm from the signal source, a 50 μ g limit of detection (SNR = 2.0) was calculated. Due to the short-
range nature of magnetic fields, this value can be significantly improved if the probe is moved closer to the 
signal source.  = Measured data;  = Calculated datum.
Figure 3. Range of magnetic signal. The magnetic signal from a simulated lymph node approximately 
6 mm in diameter decays at a lower rate than predicted by theoretical inverse-cubed law for magnetic 
dipoles due predominantly to the finite volume of the phantom.
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preinjection as a control. Postinjection, the MRI sequences were repeated at t = 0, 30, and 60 minutes to 
monitor the uptake of magnetic tracer into the first- and second-tier draining lymph nodes. Once the 
nodes had been identified on the MRI scans, the swine was moved to an operating theatre. Before sur-
gery, 0.5 mL of blue dye was intradermally injected in the same marked location as the magnetic tracer. 
During surgery a total of 2 first-tier draining nodes (one from each hind leg) were surgically removed. 
Both were identified in 30 and 60 minute postinjection MRI as being deep popliteal nodes (Fig. 5a). The 
blue dye was used to visualise the lymphatic vessels (Fig. 5b). In one limb, the first-tier node was visibly 
identifiable due to the blue staining from the dye, as well as brown staining from the magnetic tracer. 
Conversely, the first-tier node from the other limb was only identifiable from brown staining, with no 
apparent uptake of the blue dye (Fig. 5c). The maximum magnetic signal from each node was found by 
measuring the node at various positions. Due to variations in the level of noise between measurements, 
SNR was favoured over outright DC signal as a cross-measurement indicator of signal strength and 
quality. Although both ex vivo nodes (N1 and N2) were of comparable size, the SNR from N1 (7.8) was 
smaller than that of N2 (SNR of 12.4, see Fig. 6a).
In this study, resected nodes were also used to measure the spatial resolution of the MTJ probe in 
a simulated close-packed node scenario. To do this, a one-dimensional array of lymph nodes (each of 
approximately 10 – 15 mm in largest dimension with adipose tissue and adventitia intact) was made using 
N1 and N2, and one negatively measured ‘control’ node (from the groin of the animal). As before, the 
probe was mounted vertically and the translational stage was used to control node displacement. As the 
uptake of tracer was non-uniform throughout the node samples (most concentrated where the primary 
afferent vessel entered the node), N1 and N2 were orientated such that the region of highest tracer 
accumulation was facing the probe. All nodes were positioned such that their top surface was 1.0 mm 
from the probe tip. Scanning the node array with the magnetometer probe showed excellent distinction 
between the simulated ‘sentinel’ and ‘non-sentinel’ nodes (Fig. 6b). The level measured from N1 and N2 
remained above the threshold level (SNR of 5.3 and 7.3, respectively), yet the signal from the control 
node remained below the threshold level.
In vivo measurement of swine lymph nodes. Intraoperative measurements of first-tier draining 
nodes were performed across two swine. As described above, a 10 mg dose of magnetic tracer was intra-
dermally administered and MRI was used to localise the SLN(s) before surgery. Blue dye was then used 
to visualise the lymphatics and map the draining from the injection site. After visual identification of 
the nodes during surgery, the magnetometer probe was used to measure the signal of each node from a 
range of positions. When the maximum strength signal was identified, the node was measured 3 times 
at that location and the signal from the node referenced to the surrounding, non-lymphatic tissue. As 
before, a node was considered positive if the average maximum signal from the node was greater than 
the probe threshold level (i.e. SNR = 2.0). After excision, the signal from all nodes was measured once 
more ex vivo by comparing the node signal to the local background.
A total of 6 first-tier (also identified as deep popliteal; n = 2 + 4) and 2 second-tier (identified as super-
ficial inguinal; n = 1 + 1) draining nodes were identified with preoperative MRI due to the uptake of the 
magnetic tracer. During surgery, all first-tier nodes were visually identifiable from the dark brown stain-
ing of the magnetic tracer, yet only 4 of these were also identifiable with the blue dye. All first-tier nodes 
that showed a presence of magnetic tracer on the MRI scans were measured above the probe threshold 
(Fig.  6a), and confirmed with ex vivo measurement. First-tier nodes (N3 and N4) were removed from 
the hind legs of the first animal, and first-tier nodes (N5a, N5b, N6a, and N6b) were removed from the 
hind legs of the second animal. The SNRs for N3 – N6b were 6.7, 2.8, 5.2, 8.2, 8.3, and 2.8, respectively. 
Both of the second-tier nodes identified with MRI were measured with the probe and were above the 
Figure 4. Spatial resolution of probe. Normalised response curve of a point-source phantom (centred at 
x = 0) scanned at a height of 1.0 mm. A probe spatial resolution of 4.0 mm can be determined from the 
response curve’s FWHM, which is considerably less than that of a coil magnetometer or gamma probe.
www.nature.com/scientificreports/
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threshold level (SNR of 3.5 and 4.5, respectively). During surgery, drainage of the blue dye to an addi-
tional second-tier node was observed in each animal. These additional nodes did not register a signal 
when measured with the magnetometer probe, which is supported by the absence of strong negative 
contrast of these nodes in postinjection MRI scans.
Through Prussian blue staining of node sections, it was found that in all positively measured nodes 
from the in vivo experiment, significant blue staining in afferent trabecula and subcapsular sinuses was 
observed (Fig. 6c). Likewise, Prussian blue staining of negatively measured nodes (2 second-tier, 5 con-
trol nodes) revealed little to no presence of magnetic tracer.
Discussion
A handheld magnetometer probe based on MTJ technology has been developed. Based on the specific 
requirement of intraoperative detection of SLNs, the main design criteria were high sensitivity and high 
spatial resolution. An advanced prototype has been fabricated and validated in a preclinical study using 
swine as a large animal model. The observed detection limit of 50 μ g of magnetic tracer equates to 0.25% 
of an injected dose (ID) for a clinically relevant 20 mg dose of magnetic tracer. Accumulation of lympho-
tropic magnetic tracers in SLNs is highly dependent on a number of factors, including the type of cancer, 
administration route, and the physicochemical properties of the tracers (mostly the hydrodynamic diam-
eter)19 For a relatively standard 18 MBq dose of filtered 99 m-technetium sulfur colloid administered 
intradermally in breast cancer patients, average SLN accumulation is around 2.5 ± 4.9 (s.d.)%20.
Based on the magnetometer probe’s longitudinal sensitivity characteristics, the detection limit can be 
significantly increased if the probe-to-node distance is reduced. Unlike the standard inverse-cubed decay 
of fields from magnetic dipoles, the decay of the magnetic signal is largely dependent on three factors: 
the finite volume of the magnetic source, finite size of the sensing volume of the magnetometer probe, 
and the architecture of the magnetic flux density from the excitation coil. As the sensing volume and 
magnetic flux density remain constant for the magnetometer probe, then changes to the range will be 
largely affected by the size/shape of the signal sources (i.e. accumulation in the sentinel node). From the 
Figure 5. ‘Sentinel’ node identification in vivo.(a) Preinjection and postinjection coronal MRI scans of 
a swine’s hind legs showing the negative contrast in one first-tier node (circled) resulting from the uptake 
of the magnetic tracer. Postinjection scans were used preoperatively to identify the location and number 
of first-tier nodes in both limbs for each animal. (b) After the anatomical location of the nodes had been 
determined with MRI, Patent Blue V dye was used to guide the surgery, and the identification of first-tier 
nodes (circled). (c) Some nodes were only visualised due to the dark brown staining from magnetic tracer 
accumulation (top). Compared to a control lymph node (bottom left), either blue dye (bottom right) or 
magnetic tracer uptake was sufficient to distinguish the nodes from surrounding tissue.
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measured data, the magnetic signal decay for a small (6 mm diameter), homogenous concentration of 
tracer can be modelled with a cubic polynomial function (true for 0 mm < x < 7.5 mm). As a result, and 
with reference to Fig. 3, the signal measured for this sample at a distance of 4.0 mm is approximately 10% 
of the signal at 0.0 mm. This indicates the magnetometer probe would be most effective when measuring 
nodes with tracer uptake concentrated close to the node surface; where it can be measured at very close 
range and the limit of detection would approach 5 μ g of magnetic tracer, or 0.03% of a 20 mg injected 
dose.
During preclinical large animal studies using swine, uptake of the magnetic tracer in lymph nodes 
resulted in significant negative contrast on the postinjection MRI scans, providing an anatomically 
detailed roadmap to assist surgical removal of draining nodes. Across magnetometer probe measure-
ments of first-tier nodes, there was significant variation in the magnetic signal strength, which is likely 
the result of a combination of factors:
Primarily, variation in lymph node uptake is expected to occur between animals and even between 
limbs in the same animal. This is demonstrated by the significant variation in size of the 8 first-tier 
nodes (ranging from 4 mm to 15 mm in largest dimension). Variation in size can have a number of 
effects, such as variation in the uptake between nodes, and variation in the concentration of the tracer 
within the node. Another factor affecting the magnetometer probe’s signal magnitude was the varying 
level of adventitia and adipose tissue surrounding in vivo first-tier nodes. This can limit the distance of 
the probe to the node, and in some cases, the adipose tissue surrounding the node had to be partially or 
fully resected during surgery to sufficiently expose the node and register a signal with the magnetometer 
probe.
The presence of tissue in the vicinity of the probe tip introduces a secondary effect: reduction in the 
magnetic signal in vivo due to the negative susceptibility (and hence diamagnetic nature) of surrounding 
tissue. Using a simple mathematical approximation, more than 0.4 μ g of iron oxide nanoparticles would 
be required per 1.0 cm3 of tissue to counteract this diamagnetic effect and be measured by a coil or 
induction-based magnetometer21. However, the impact of diamagnetic tissue on overall signal strength 
is expected to be low for the MTJ magnetometer probe, given the large dependence of signal strength 
on distance from the probe tip. Using the measured range (Fig. 3) and spatial resolution (Fig. 4) of the 
MTJ magnetometer probe, the sensing volume can be approximated with that of a cone (i.e. ~ 0.03 cm3). 
Based on the above calculation, it is approximated that the limit of iron oxide detection due to diamag-
netic interference would be 0.01 μ g of tracer – a value much lower than the previously calculated 5 μ g of 
tracer required for detection using the MTJ magnetometer probe.
Although the factors above must be considered for the application of the magnetometer probe in the 
intraoperative setting, variation in signal between nodes in vivo was not found to be of consequence. This 
Figure 6. Swine lymph node measurements. (a) MTJ magnetometer probe measurement of first-tier nodes 
from three animals. N1, N2, and control (Cont.) were measured ex vivo, and N3 – N6b were measured in 
vivo. Error bars indicate the uncertainty in measurement due to background signal fluctuations (electronic 
noise). (b) Distinguishing nodes in close proximity in ex vivo array of lymph nodes. The boundary of each 
node is indicated with the vertical dotted lines and the threshold level is indicated with the horizontal dotted 
line. (c) Prussian blue staining of two separate node sections. The presence of magnetic tracer in afferent 
trabecula and subcapsular sinuses is evident in positive first- and second-tier nodes (e.g. top), but absent in 
negative nodes (e.g. bottom).
www.nature.com/scientificreports/
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is because only binary, qualitative (positive / negative) detection is required to locate the SLN; and this 
can be adequately achieved as long as the signal is above the predetermined threshold value.
By analysing the Prussian blue stained node sections under an optical microscope, the presence of 
the magnetic tracers in positively measured nodes could be confirmed. Furthermore, while the two neg-
atively measured second-tier nodes could be seen to contain a small level of magnetic tracer, there was 
a clear distinction in the quantity of magnetic tracer when compared to positively measured first-tier 
and second-tier nodes.
Besides sensitivity, the spatial resolution of the magnetometer probe is of high importance, espe-
cially for malignancies with complex lymphatic drainage such as gastrointestinal and oesophageal cancer. 
Compared to the spatial resolution of gamma probes and competing magnetometer probes such as the 
SentiMag (spatial resolution of ~20 mm22), the MTJ magnetometer probe demonstrates excellent spatial 
resolution at just 4.0 mm. From the spatial resolution, the magnetometer probe’s ability to differentiate 
a SLN signal from an injection site’s background signal can also be determined. For gamma probes, a 
SLN must be a minimum distance equal to 3 standard deviations of the response curve from an injection 
site to minimise erroneous readings due to gamma shine-through23 For a probe with a spatial resolu-
tion of 20 mm, this distance equates to > 25 mm, but for the MTJ magnetometer probe, only a distance 
of > 5 mm would be required. Resolution of this order may offer a significant advantage in complex, 
close-packed lymphatic environments, as further demonstrated in the ex vivo spatial resolution meas-
urements presented in Fig. 6b.
In a simulated close-packed array of lymph nodes, the probe demonstrated the ability to accurately 
distinguish positive (sentinel) nodes from control nodes with near-pinpoint precision. These experiments 
demonstrate the potential for the MTJ magnetometer probe to be applied beyond breast cancer and mel-
anoma to more complex cancer types such as oesophageal, and other deep tissue cancers of the abdomen.
Methods
Magnetometer probe. Highly sensitive (2 nT/Hz05 at 100 Hz) single-axis MgO-based MTJ sensors 
were purchased from MicroMagnetics (STJ-201, Massachusetts, USA). Ultrasonic wedge bonding of alu-
minium wire between the contact pads of the MTJ sensors and contact pads on the sensor PCB was 
required due to the small size of each device. Conventional soldering was used for all other electronic 
components. Electromagnet for the probe tip was machined out of mild steel into a cylindrical bobbin 
shape 25 mm long, and with a hollow, central aperture 4.0 mm in diameter for the sensor PCB to sit 
within. Output signals from the probe were acquired via DAQ6009 hardware (National Instruments, 
Texas, USA) into a custom LabVIEW executable. Detected signals from the magnetic tracer were 
graphed in real time to provide user feedback during use of the probe. All data were saved to a data file 
for computational analysis.
Measuring magnetic particles. Iron oxide nanoparticles with a dextran coating were purchased 
from Chemicell (FluidMag-DX, Berlin, Germany) for use in magnetic phantoms during in vitro char-
acterisation, and as a lymphotropic tracer in large animal experiments. The hydrodynamic diameter of 
the tracer was measured using dynamic light scattering to be 28 nm with a distribution width of 20 nm. 
Changes in tracer size distribution were measured over a wide range of pH levels (1.5 to 11), as well as 
in saline and phosphate buffer solution, with no significant changes to stability evident. Two types of 
dried magnetic phantom were constructed for use with the magnetometer probe: nonpoint-source (NPS) 
and ‘point-source’ (PS) phantoms. NPS phantoms were used for sensitivity measurements, and were con-
structed by cementing glass coverslips to the face of 4.0 mm thick polyoxymethylene discs with a 5.0 mm 
central aperture, creating a small well. Controlled volumes of magnetic tracer were dried in the wells, 
creating a thin, uniform layer of magnetic particles at the bottom of the well. PS phantoms were used for 
in vitro spatial resolution measurements and were constructed by creating a 3.0 mm diameter aperture in 
a 1.5 mm thick polycarbonate disk, and laminating it to another equally sized disk without an aperture, 
creating a smaller volume well. Similarly, quantities of magnetic tracer were dried in the well, but due to 
the small aperture size and viscosity of the tracer, the result was a volume of dried particles of similar 
dimensions to the well, rather than a thin layer at the bottom. In order to determine the quantity of tracer 
in each phantom, 0.1 mL of the stock was dissolved in 36% HCl solution, which was added to an aqueous 
solution of K4[Fe(CN)6]. After 3 minutes, the UV-Vis absorption spectrum of the solution was measured 
from 500 – 800 nm, and the intensity of the spectrum was compared to a calibration curve from known 
concentrations of FeCl3 solution to determine the iron content. For all measurements, the uncertainty in 
a signal was taken as the ± 1 standard deviation of variation in the measured background signal, and the 
noise level as ± 3 standard deviations. The noise level calculated in this manner was used to find the SNR.
Large animal experiments. Pre-clinical large animal experiments using swine were carried out in 
accordance with the National Health and Medical Research Council’s Australian code of practice for the 
care and use of animals for scientific purposes. All experimental protocols using animals were approved 
by both Adelaide University and National Imaging Facility animal ethics. In total, three female Large 
White swine (31 – 35 kg) were used across two preclinical studies. For all the swine studies, the magnetic 
tracer was prepared to a 20 mg/mL concentration in 0.9% saline, and injected without further purifi-
cation. Patent Blue V dye was prepared according to manufacturer’s instructions and used to visually 
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identify the lymphatic vessels leading to draining lymph nodes. T1 sequences were acquired using the 
following parameters: TR/TE 1530 ms/4.08 ms, flip angle 15°, FOV phase 75%, 5 mm slice thickness (axial 
and coronal). T2* sequences were acquired using: TR/TE of 155 ms/10 ms, flip angle of 90°, FOV phase 
of 75%, 5 mm slice thickness (axial and coronal). Excised nodes were stored in a 10% formalin solution 
with any surrounding adventitia or adipose tissue left intact, unless sectioned for Prussian blue staining. 
If used for staining, nodes < 5 mm in size were halved, and nodes > 5 mm were sliced into 3 – 5 mm sec-
tions and embedded in paraffin wax blocks. Two slices of 4 μ m thickness were taken from each embed-
ded node section for haematoxylin and eosin (H&E) and Prussian blue staining, respectively.
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